Research map: Tildrakizumab for Systemic‐Treatment‐Eligible Plaque Psoriasis: A Retrospective Real‐World Study in Chinese Patients

Back to the article

Papers in this map

  1. Psoriasis · Christopher E.M. Griffiths · 2021 · 2400 citations · Cited by this paper
  2. A Comparison Between the Therapeutic Efficacy and Safety of Microneedling With Ascorbic Acid Versus CO 2 Fractional Laser With Ascorbic Acid in the Treatment of Striae · 2026 · Related
  3. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis · Kamran Ghoreschi · 2021 · 673 citations · Cited by this paper
  4. The Role of Oxygen Tension in Modulating Wound Healing Phases · 2026 · Related
  5. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials · Kristian Reich · 2017 · 568 citations · Cited by this paper
  6. 5‐Aminolevulinic Acid–Based Photodynamic Therapy (ALA‐PDT) for Bowen’s Disease in Chinese Patients: A Multicenter Prospective Study · 2026 · Related
  7. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council · Bruce E Strober · 2019 · 258 citations · Cited by this paper
  8. Efficacy and Safety of Mesotherapy With 0.5% Minoxidil Versus Topical 2% Minoxidil for Female Androgenetic Alopecia: A Randomized Controlled Trial · 2026 · Related
  9. Psoriasis · April Wang Armstrong · 2025 · 187 citations · Cited by this paper
  10. Insights Into the Role of Mitophagy and Immune Infiltration in Keloids · 2026 · Related
  11. Current Concepts of Psoriasis Immunopathogenesis · Marijana Vičić · 2021 · 164 citations · Cited by this paper
  12. The Efficacy and Safety of Ablative Fractional CO 2 Laser Combined With Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial · 2026 · Related
  13. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients · Katharina Antonia Drerup · 2021 · 49 citations · Cited by this paper
  14. Neutrophil‐to‐Lymphocyte Ratio Dynamics and Progression‐Free Survival in Advanced Cutaneous Squamous Cell Carcinoma Treated With Cemiplimab · 2026 · Related
  15. Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study— IL PSO ( Italian landscape psoriasis ) · Alessandra Narcisi · 2022 · 48 citations · Cited by this paper
  16. Medical Complications of Tattooing: A Bicentric Retrospective Study · 2026 · Related
  17. Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT · Athanasios Tsianakas · 2022 · 45 citations · Cited by this paper
  18. Acute Pain Features Predictive of Postherpetic Neuralgia Development: A Retrospective Analysis of Herpes Zoster Cases · 2026 · Related
  19. Tildrakizumab for the treatment of moderate to severe psoriasis: Results from a single center preliminary real‐life study · Angelo Ruggiero · 2022 · 40 citations · Cited by this paper
  20. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition） · Committee on Psoriasis · 2023 · 38 citations · Cited by this paper
  21. Tildrakizumab: First Global Approval · Anthony Markham · 2018 · 36 citations · Cited by this paper
  22. Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study · Giacomo Caldarola · 2022 · 30 citations · Cited by this paper
  23. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate‐to‐severe plaque psoriasis patients in conditions close to clinical practice · Antonio Costanzo · 2023 · 30 citations · Cited by this paper
  24. A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients · Elena Campione · 2023 · 29 citations · Cited by this paper
  25. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis · Yves P. Poulin · 2020 · 25 citations · Cited by this paper
  26. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group · Sonsoles Berenguer‐Ruiz · 2023 · 18 citations · Cited by this paper
  27. Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension · Yu Chen · 2024 · 16 citations · Cited by this paper
  28. Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis · Eugenia Veronica Di Brizzi · 2023 · 14 citations · Cited by this paper
  29. Tildrakizumab in Complex Psoriatic Patients: An Experience in Emilia-Romagna (Italy) · Federico Bardazzi · 2023 · 13 citations · Cited by this paper
  30. Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023 · Jinger Lin · 2024 · 13 citations · Cited by this paper
  31. Quality of life and patient-reported symptoms in a Phase 4, real-world study of tildrakizumab in patients with moderate-to-severe psoriasis: Week 28 interim analysis · Neal D Bhatia · 2023 · 12 citations · Cited by this paper
  32. Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain) · Ricardo Ruíz‐Villaverde · 2022 · 11 citations · Cited by this paper
  33. Interleukin 23 inhibitors for psoriasis: not just another number · Hervé Bachelez · 2017 · 10 citations · Cited by this paper
  34. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States · Xiaoying Jia · 2020 · 9 citations · Cited by this paper
  35. Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting · Neal D Bhatia · 2024 · 8 citations · Cited by this paper
  36. 52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience · Francisco Javier Melgosa Ramos · 2024 · 7 citations · Cited by this paper
  37. Tildrakizumab in Psoriatic Patients With Current or Past Malignancy: A Real‐Life Cohort and Literature Review · Ofelia Baniandrés · 2025 · 4 citations · Cited by this paper
  38. Real‐World Effectiveness, Safety and Drug Survival of Tildrakizumab in Adult Patients With Plaque Psoriasis: A 2‐Year Portuguese Multicenter Retrospective Cohort Study · Tiago Torres · 2025 · 3 citations · Cited by this paper
  39. Real-World Effectiveness and Safety of Tildrakizumab in Moderate-to-Severe Psoriasis: A Multicenter Experience in the Basque Country · R. Izu · 2025 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)